Four months after losing partner AstraZeneca plc upon mixed cardiovascular data, AtheroGenics Inc. plans to start looking for a new collaborator, as patient enrollment gets underway in a Phase III trial of its oral anti-inflammatory antioxidant drug, AGI-1067, in diabetes.(BioWorld Today) Read More